Celecoxib as an Adjuvant to Fluvoxamine in Moderate to Severe Obsessive-compulsive Disorder: A Double-blind, Placebo-controlled, Randomized Trial

Abstract

The results of the current study suggest that celecoxib could be a tolerable and effective adjunctive treatment for more rapid and more satisfying improvements in OCD symptoms.

Therapeutic Implications of Brain–Immune Interactions: Treatment in Translation

“…The 4 studies showed a positive benefit for celecoxib at some point in the trial, although the one study conducted in Germany was plagued by a dropout rate of 50% in the celecoxib group and 60% in the placebo group (Muller et al, 2006), and of the remaining 3 studies, all of which were conducted in Iran, one showed no effect at 8 weeks (Hashemian et al, 2011); yet, for unclear reasons, in each meta-analysis, the more positive 4-week data from this study (that appear in the literature as an abstract) are included in the efficacy evaluation (Muller et al, 2006;Akhondzadeh et al, 2009;Hashemian et al, 2011;Abbasi et al, 2012). Of note, the Iranian group has also published positive data for celecoxib in OCD, acute bipolar mania, and depression in breast cancer, indicating an extraordinary efficacy that warrants further evaluation (Arabzadeh et al, 2015;Mohammadinejad et al, 2015;Shalbafan et al, 2015). Finally, there are some data to support that acetylsalicylic acid may augment the response to conventional antidepressant therapy, although this is a small literature that is in need of larger studies (Mendlewicz et al, 2006).…”

N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled trial

“…Patients were visited to evaluate response to therapy using Y‐BOCS (experts’ rating version) at baseline, fourth, eighth and tenth weeks. Y‐BOCS has been used to evaluate treatment efficacy and severity of OCD in several clinical trials in Iran . The primary outcome measure was difference in Y‐BOCS total score change from baseline to the end of the trial between the two groups.…”

L-carnosine as an adjuvant to fluvoxamine in treatment of obsessive compulsive disorder: A randomized double-blind study

“…Differences in score change of the Y‐BOCS obsession and compulsion subscales from baseline to week 10 as well as differences in score change of total and subscale scores from baseline to other time points were assigned as secondary outcome measures. Other secondary outcome measures included differences in partial response rates (defined as between 25 to 35% reduction in Y‐BOCS score), complete response rates (≥35% reduction in Y‐BOCS score) and remission rates (score ≤14) between the two groups (Öst, Riise, Wergeland, et al, ; Pallanti & Quercioli, ; Shalbafan, Mohammadinejad, Shariat, et al, ). A thorough physical examination was conducted at each visit.…”